S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:DNAY

Telesis Bio - DNAY Stock Forecast, Price & News

$1.36
-0.09 (-6.21%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.36
$1.45
50-Day Range
$1.36
$1.93
52-Week Range
$1.35
$11.32
Volume
69,317 shs
Average Volume
99,144 shs
Market Capitalization
$40.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Telesis Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
267.6% Upside
$5.00 Price Target
Short Interest
Bearish
3.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Telesis Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.85) to ($1.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

457th out of 1,047 stocks

Analytical Instruments Industry

16th out of 28 stocks

DNAY stock logo

About Telesis Bio (NASDAQ:DNAY) Stock

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Receive DNAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter.

DNAY Stock News Headlines

Telesis Bio, Inc. (DNAY) Q3 2022 Earnings Call Transcript
DNAY Codex DNA, Inc.
DNAY, MULN and ASPN among pre markets gainers
Codex DNA: Q1 Earnings Snapshot
See More Headlines
Receive DNAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter.

DNAY Company Calendar

Last Earnings
11/08/2022
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/28/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNAY
Fax
N/A
Employees
212
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+267.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-38,960,000.00
Net Margins
-251.04%
Pretax Margin
-250.94%

Debt

Sales & Book Value

Annual Sales
$11.04 million
Book Value
$1.81 per share

Miscellaneous

Free Float
20,606,000
Market Cap
$40.15 million
Optionable
Not Optionable
Beta
1.38

Key Executives

  • Dr. Todd R. Nelson MBA (Age 55)
    Ph.D., Pres, CEO & Director
    Comp: $876.78k
  • Mr. Daniel G. Gibson Ph.D. (Age 45)
    Chief Technology Officer
    Comp: $436.54k
  • Mr. Brent M. Hunter
    Principal Financial Officer & Principal Accounting Officer
  • Mr. Eric Esser (Age 52)
    Chief Operating Officer
  • Richard Lepke
    Director of Investor Relations
  • Mr. Robert H. Cutler (Age 54)
    Chief Legal Officer
  • Ms. Laura B. Puga M.B.A. (Age 42)
    VP of People & Culture
  • Mr. Decky Goodrich M.B.A.
    Sr. VP of Commercial Operations
  • Mr. Laurence Warden
    Sr. VP of Engineering & Instrumentation













DNAY Stock - Frequently Asked Questions

Should I buy or sell Telesis Bio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Telesis Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DNAY shares.
View DNAY analyst ratings
or view top-rated stocks.

What is Telesis Bio's stock price forecast for 2023?

2 equities research analysts have issued 1 year price targets for Telesis Bio's stock. Their DNAY share price forecasts range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 267.6% from the stock's current price.
View analysts price targets for DNAY
or view top-rated stocks among Wall Street analysts.

How have DNAY shares performed in 2022?

Telesis Bio's stock was trading at $10.80 at the beginning of the year. Since then, DNAY shares have decreased by 87.4% and is now trading at $1.36.
View the best growth stocks for 2022 here
.

Are investors shorting Telesis Bio?

Telesis Bio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 325,700 shares, an increase of 22.7% from the October 31st total of 265,400 shares. Based on an average daily trading volume, of 73,400 shares, the short-interest ratio is presently 4.4 days. Currently, 3.8% of the company's shares are sold short.
View Telesis Bio's Short Interest
.

When is Telesis Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our DNAY earnings forecast
.

How were Telesis Bio's earnings last quarter?

Telesis Bio, Inc. (NASDAQ:DNAY) issued its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.06. The firm earned $6.68 million during the quarter, compared to the consensus estimate of $5.30 million. Telesis Bio had a negative net margin of 251.04% and a negative trailing twelve-month return on equity of 73.65%.

What guidance has Telesis Bio issued on next quarter's earnings?

Telesis Bio issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $23.00 million-$25.00 million, compared to the consensus revenue estimate of $23.03 million.

When did Telesis Bio IPO?

(DNAY) raised $100 million in an IPO on Friday, June 18th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and KeyBanc Capital Markets served as the underwriters for the IPO.

What is Telesis Bio's stock symbol?

Telesis Bio trades on the NASDAQ under the ticker symbol "DNAY."

Who are Telesis Bio's major shareholders?

Telesis Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Penbrook Management LLC (0.91%) and K.J. Harrison & Partners Inc (0.05%).

How do I buy shares of Telesis Bio?

Shares of DNAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Telesis Bio's stock price today?

One share of DNAY stock can currently be purchased for approximately $1.36.

How much money does Telesis Bio make?

Telesis Bio (NASDAQ:DNAY) has a market capitalization of $40.15 million and generates $11.04 million in revenue each year. The company earns $-38,960,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does Telesis Bio have?

The company employs 212 workers across the globe.

How can I contact Telesis Bio?

The official website for the company is codexdna.com. The company can be reached via phone at 858-228-4115 or via email at ir@codexdna.com.

This page (NASDAQ:DNAY) was last updated on 12/2/2022 by MarketBeat.com Staff